<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20090203001637N14</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-02-11</date_registration>
      <primary_sponsor>Research Deputy of Tarbiat Modares University</primary_sponsor>
      <public_title>The effect of virtual reality exercise therapy in the treatment of chronic low back pain patients with high central sensitization.</public_title>
      <acronym>CS (Central ensitization)</acronym>
      <scientific_title>The effects of exercise therapy with VR on sensory, psychosocial symptoms, and electromyographic activity of trunk muscles during functional tasks in chronic low back pain patients with high central sensitization.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-04-11</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>22</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>https://irct.ir/trial/81041</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization will be performed using sealed, numbered envelopes, each containing the group allocation. Participants will receive an envelope upon enrollment, ensuring allocation concealment and minimizing selection bias, Blinding description: To prevent assessment bias, evaluators will be blinded to the patients' group allocation (intervention or control).</study_design>
      <phase>N/A</phase>
      <hc_freetext>non-specific low back pain (LBP) with high levels of central sensitization.</hc_freetext>
      <i_freetext>Intervention group:Individuals in this group will play games and exercise with the Xbox 360 Kinect for 30–45 minutes and should not have a history of using the Kinect or engaging in strenuous professional exercise. Each session will include a 10-minute warm-up and 5-minute cool-down. Exercise will be performed at a distance of 3 meters from the device and a 48-inch screen, and rest will be allowed if fatigue occurs. Exercise intensity will be maintained at 64–76% HRmax by monitoring heart rate. Games will be selected from Kinect Adventures and intensity will be adjusted by changing time or repetitions as needed. If pain or disability increases, exercise will be stopped or the individual will be withdrawn from the study..</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
File of intervention program protocol and statistical analysis plan through publication of thesis and writingan article

When:
Starting 6 months after publication of results

To whom:
The research team of this study and other clinical academic researchers who are studying in favor of these patients.

Conditions:
Researchers who intend to write a meta-analysis or systematic review articles are allowed to access document.

Where to obtain:
Sedighe Kahrizi ; Behdokht Dehqan

How to obtain:
The request will be responded after getting the approval of university or the academic institution

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Behdokht Dehqan</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Tarbiat Modares University, Jalale al e ahmad Ave, Kouye Nas</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1411713116</zip>
        <telephone>+98 21 8609 3437</telephone>
        <email>behdokht.dehqan@odares.acir</email>
        <affiliation>Tarbiat Modares University</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Sedighe Kahrizi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Tarbiat Modares University,Jalale al e ahmad Ave, Kouye Nasr</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1411713116</zip>
        <telephone>+98 21 8828 4511</telephone>
        <email>Kahrizis@modares.ac.ir</email>
        <affiliation>Tarbiat Modares University</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>History of low back pain for at least 3 months as defined by the US National Institutes of Health as non-specific low back pain.
Having an average pain intensity between 3 and 7 at the time of study entry
Having a score of 40 or higher on the Central Sensitivity Questionnaire
No pain medication for 48 hours prior to assessment and intervention.
No abnormalities in skin sensation.
Scoring above 23 on the Mini-Mental State Examination (MMSE).</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Having intervertebral disc problems and nerve involvement (such as disc herniation, spondylosis, spondylolisthesis, and radiculopathy) and a history of any related surgery
History of cardiovascular, respiratory, rheumatic, neurological, malignancy, and infection diseases
Pain intensity higher than 7 and lower than 3 based on VAS on the day of the test
Pregnancy
Body mass index (BMI) higher than 25 kilograms per square meter
Vision and hearing impairment
Having a confirmed disorder of the vestibular and balance system
Unwillingness to continue cooperation
Inability to learn and correctly execute an exercise program
Missing the inclusion criteria for the treatment period</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>central se</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>central sensitization</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Devices</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group:Individuals in this group will play games and exercise with the Xbox 360 Kinect for 30–45 minutes and should not have a history of using the Kinect or engaging in strenuous professional exercise. Each session will include a 10-minute warm-up and 5-minute cool-down. Exercise will be performed at a distance of 3 meters from the device and a 48-inch screen, and rest will be allowed if fatigue occurs. Exercise intensity will be maintained at 64–76% HRmax by monitoring heart rate. Games will be selected from Kinect Adventures and intensity will be adjusted by changing time or repetitions as needed. If pain or disability increases, exercise will be stopped or the individual will be withdrawn from the study.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Central Sensitization Questionnaire. Timepoint: One day before the start of the intervention and one day after the end of the intervention for four weeks (12 sessions). Method of measurement: Central Sensitivity Questionnaire, Persianized version.</prim_outcome>
      <prim_outcome>Pain Pressure Threshold. Timepoint: One day before the start of the intervention and one day after the end of the intervention for four weeks (12 sessions). Method of measurement: Algometer.</prim_outcome>
      <prim_outcome>Pain. Timepoint: One day before the start of the intervention and one day after the end of the intervention for four weeks (12 sessions). Method of measurement: VAS.</prim_outcome>
      <prim_outcome>Pain Catastrophizing. Timepoint: One day before the start of the intervention and one day after the end of the intervention for four weeks (12 sessions). Method of measurement: Persian version of the Pain Catastrophizing Questionnaire.</prim_outcome>
      <prim_outcome>TSK Questionnaire. Timepoint: One day before the start of the intervention and one day after the end of the intervention for four weeks (12 sessions). Method of measurement: Persian version of the TSK Questionnaire.</prim_outcome>
      <prim_outcome>Oswestry Disability. Timepoint: One day before the start of the intervention and one day after the end of the intervention for four weeks (12 sessions). Method of measurement: Persian version of the Oswestry Disability Questionnaire.</prim_outcome>
      <prim_outcome>Electromyographic activity of trunk muscles. Timepoint: One day before the start of the intervention and one day after the end of the intervention for four weeks (12 sessions). Method of measurement: Surface Electromyography device.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Research Deputy of Tarbiat Modares University</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2025-11-01</approval_date>
        <contact_name>Ethics committee of Tarbiat modares University</contact_name>
        <contact_address>Tehran, Jalal Al-Ahmad, Nasr Crossing, Tarbiat Modares University Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
